Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses’. Osel’s approach of repopulating the microbiome with beneficial bacteria helps restore healthy and protective microbiomes.
The primary focus of our work is women’s health, with indications including recurrent urinary tract infections and bacterial vaginosis. Our secondary focus is disorders of the gastrointestinal tract. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.
Peter P. Lee, Founder and Executive Chairman
Dr. Lee has published more than 100 articles in peer-reviewed journals and received significant grant awards from the National Institutes of Health, US Department of Defense, and Stand Up To Cancer. He is an elected member of the American Society for Clinical Investigation.
Laurel A. Lagenaur, PhD, Director of Research
Tom Parks, PhD, Director of Product Development
Michael Cannon, Board Member
Sandy Chau, Board Member
Robert Lee, Board Member
Craig Cohen, MD, MPH
Craig R. Cohen, MD, MPH is one of the leading reproductive infectious disease experts in the world. He is professor of obstetrics, gynecology & reproductive sciences at the University of California San Francisco (UCSF), and co-director of the University of California Global Health Institute. Dr. Cohen has collaborated with Osel Inc. since 2007 in the clinical development of LACTIN-V through Phase 1, 2a, and 2b studies. In addition, he served as principal investigator of a grant from NIAID/NIH for the pre-clinical development of MucoCept-CVN, the lead MucoCept product candidate.
Dr. Cohen has over 28 years of experience leading clinical and translational investigations to improve women’s reproductive health. His work focuses on two major areas: 1) development of live biotherapeutic products, like LACTIN-V and MucoCept-CVN, to prevent bacterial vaginosis and its sequelae, and 2) HIV care and prevention research in developing countries.
Dr. Cohen completed his MD at the University of Louisville, obstetrics & gynecology residency at Northwestern University, and fellowship in reproductive infectious disease and Masters of Public Health at the University of Washington. In 2003 he joined the faculty at UCSF. Since then he has raised over $200 million in grants and contracts from the NIH, CDC, Bill & Melinda Gates Foundation, Doris Duke Charitable Foundation, Children’s Investment Fund Foundation and through private philanthropy. Dr. Cohen has published over 250 peer-reviewed publications leading to over 14,000 citations. In addition, in 2020 he became the founding editor-in-chief of Advances in Global Health published by UC Press.
Gary Schoolnik, MD
Gary Schoolnik, MD, is Professor of Medicine (Emeritus, Active) in the Department of Medicine, Division of Infectious Diseases at Stanford Medical School. He is also Associate Director of the Institute for Immunology, Transplantation and Infection at the university and is an Attending Physician in Internal Medicine and Infectious Diseases at Stanford University Hospital.
Dr. Schoolnik attended Stanford University. He received his MD degree from the University of Washington in Seattle and was Intern, Resident and Chief Resident in Internal Medicine at the Massachusetts General Hospital in Boston. Dr. Schoolnik was an Associate Physician and Research Associate in microbial biochemistry and genetics at The Rockefeller University in Manhattan before joining the Stanford Medical School faculty.
Dr. Schoolnik’s research has focused on the genetics, genomics and systems biology of pathogenic microbes. He led the Gates Foundation funded tuberculosis genome sequence and bioinformatics database, TBDB.org, and was PI of the NIH-funded Systems Biology of M. tuberculosis international consortium “TBSysBio”. He served on the NIAID National Advisory Council and co-chaired the NIH’s Blue Ribbon Committees on Bioterrorism as well as the committee on the Human Microbiome. Dr. Schoolnik is the founding editor of the journal Molecular Microbiology. While at Stanford he served as Chief of the Division of Infectious Diseases and Geographic Medicine, and as Associate Dean, office of Academic Affairs.